California-based Guardant Health, a precision oncology company, has named Leena Das-Young, Pharm D as the new general manager of its LUNAR program, it was reported yesterday.

In the new role, Dr Das-Young will manage all work applying the company's technology and database of more than 70,000 clinical Guardant360 assay results, toward new applications in early-stage cancer, such as residual detection, recurrence monitoring, and early detection of cancer.

Dr Das-Young was most recently the vice president & head of the Late Phase Strategy and Development Group in Pfizer in the Oncology group and was responsible for a portfolio of oncology programs including Ibrance, Xalkori, Besponsa, Sutent, lorlatinib, and others. Prior to her roles in product development, she served in increasingly senior commercial roles responsible for several successful launches at both Pfizer and Bayer.